Latest Ratios: P/E Ratio -1.2x · EV/EBITDA N/A · ROE -700.1%. (2021–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Market Cap | $7M | $9M | — | — | — |
| Enterprise Value | $8M | $10M | — | — | — |
| P/E Ratio → | -1.19 | — | — | — | — |
| P/S Ratio | — | — | — | — | — |
| P/B Ratio | 6.19 | 7.88 | — | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| ROE | -700.1% | -700.1% | -80.8% | -54.3% | -108.1% |
| ROA | -264.5% | -264.5% | -29.9% | -33.4% | -106.5% |
| ROIC | -242.3% | -242.3% | -21.1% | -27.1% | — |
| ROCE | -622.0% | -622.0% | -72.1% | -52.1% | -108.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Debt / Equity | 0.23 | 0.23 | 2.57 | 1.14 | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | 0.18 | 2.56 | 1.08 | -0.29 |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | -15.54 | -15.54 | -8.28 | -23.57 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Current Ratio | 0.13 | 0.13 | 0.00 | 0.24 | 20.12 |
| Quick Ratio | 0.13 | 0.13 | 0.00 | 0.24 | 20.12 |
| Cash Ratio | 0.05 | 0.05 | 0.00 | 0.06 | 19.88 |
| Asset Turnover | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 1.6% | 1.3% | — | — | — |
| Total Shareholder Yield | 1.6% | 1.3% | — | — | — |
| Shares Outstanding | — | $19M | $1.0B | $1.0B | $1.0B |
Imminent liquidity insolvency risk
According to recent market data, KLTO trades at a price-to-book ratio of 6.19, which appears disconnected from its distressed financial state and suggests that investors are pricing the company as a high-risk option on its intellectual property rather than on any fundamental earnings or cash flow metrics.
The lack of meaningful P/E or EV/EBITDA multiples reflects the company's pre-revenue status, rendering traditional valuation models largely inapplicable. Investors should monitor whether this premium valuation is supported by the scientific potential of the Klotho pathway or if it represents an irrational market expectation for near-term clinical success.
Based on reported figures, KLTO's ROIC has remained deeply negative, reaching -57.9% in 2025Q3, which indicates that the company is currently destroying shareholder value as it consumes capital to fund preclinical research without generating any offsetting operational returns or commercial milestones.
The trend of decaying returns on invested capital is consistent with the firm's transition from a research-heavy entity to a public company with significant administrative overhead. This persistent negative return profile warrants investigation into whether the company can ever achieve a positive cost of capital without a fundamental shift in its business model.
As reported in financial statements, the company's liquidity position is highly precarious, with a cash balance of only $63,741, which suggests that the firm may struggle to meet its near-term obligations without immediate and potentially highly dilutive capital raises to sustain its ongoing R&D activities.
While the current ratio appears artificially high at 83.69 due to the timing of equity injections, this metric is misleading given the company's lack of revenue and high burn rate. Investors should view this liquidity profile as a significant risk factor that could lead to a total cessation of operations if financing is not secured.
Based on a comparison with peers like Athira Pharma and AC Immune, KLTO's valuation appears to be driven by speculative sentiment rather than clinical maturity, as the company lacks the revenue or cash runway typically required to sustain operations in the competitive CNS biotechnology sector.
The gap between KLTO and its peers is structural, as the company's extremely limited cash reserves place it at a disadvantage compared to better-capitalized entities. This suggests that the company may be forced into unfavorable financing terms that could significantly dilute existing shareholders compared to its peers.
The current ratio is the most commonly misapplied metric for KLTO, as it obscures the company's true liquidity risk by failing to account for the high, non-discretionary burn rate inherent in pre-revenue gene therapy development, which renders standard liquidity coverage ratios largely irrelevant for assessing solvency.
Analysts should instead focus on the 'cash runway' or 'monthly burn rate' to evaluate the company's survival horizon. Relying on the current ratio may lead to a false sense of security, as it does not reflect the immediate need for capital to fund the next phase of clinical development.
Includes 30+ ratios · 4 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KLTO stock.
Klotho Neurosciences, Inc.'s current P/E ratio is -1.2x. This places it at the 50th percentile of its historical range.
Klotho Neurosciences, Inc.'s return on equity (ROE) is -700.1%. The historical average is -81.0%.
Based on historical data, Klotho Neurosciences, Inc. is trading at a P/E of -1.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.